-
公开(公告)号:WO2023021116A1
公开(公告)日:2023-02-23
申请号:PCT/EP2022/073016
申请日:2022-08-17
发明人: CHRISTIAN, Thirion , CORDULA, Pertl , ALEXANDER, Karlas , VOLKER, Sandig , INGO, Jordan , JOHANNES, Holst Peter , DITTE, Rahbæk Boilesen , RALF, Wagner , PATRICK, Neckermann , BENEDIKT, Asbach
IPC分类号: A61K39/12 , A61P31/20 , A61P35/00 , C07K14/005
摘要: The present invention relates to a nucleic acid comprising or consisting of nucleic acid sequences encoding papilloma virus proteins E1, E6, and E7; wherein said nucleic acid molecule encodes a single polyprotein.
-
公开(公告)号:WO2023275538A1
公开(公告)日:2023-01-05
申请号:PCT/GB2022/051663
申请日:2022-06-28
申请人: DIOSYNVAX LTD , THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE , UNIVERSITÄT REGENSBURG
发明人: VISHWANATH, Sneha , CARNELL, George , ASBACH, Benedikt , WAGNER, Ralf , KINSLEY, Rebecca , HEENEY, Jonathan, Luke , WELLS, David
摘要: Vaccines that induce a broadly neutralising immune response to protect against disease caused by beta-coronaviruses, especially beta-coronaviruses of the sarbecovirus and merbecovirus lineages, are described. The vaccines are provided by use of phylogenetically-, and epitope-optimised sarbecovirus and merbecovirus RBD subunits. The vaccines are provided as nucleic acid vaccines, either as separate polynucleotides, each encoding a different RBD subunit (or RBD dimer), or pieced together in a string as a single polynucleotide encoding all of the RBD subunits (or RBD dimers). The separate polynucleotides may be administered as a mixture together, co-administered, or administered sequentially in any order. Polynucleotides, polypeptides, vectors, cells, fusion proteins, pharmaceutical compositions, combined preparations, and their use as vaccines against viruses of the coronavirus family are described. Methods of inducing an immune response to, or immunising a subject against, a beta-coronavirus in a subject by administering an effective amount of a vaccine to the subject are also described.
-
3.
公开(公告)号:WO2021122239A1
公开(公告)日:2021-06-24
申请号:PCT/EP2020/085338
申请日:2020-12-09
IPC分类号: A61K31/343 , A61K31/436 , A61K31/609 , A61K31/55 , A61K38/12 , A61K45/06 , A61P1/16 , A61P13/12
摘要: The present invention relates to a compound for use in a method of treating a pathological condition selected from polycystic kidney disease, polycystic liver disease, and a combination thereof. The present invention further relates to a composition for use in a method of treating a pathological condition selected from polycystic kidney disease, polycystic liver disease, and a combination thereof.
-
公开(公告)号:WO2020245209A1
公开(公告)日:2020-12-10
申请号:PCT/EP2020/065368
申请日:2020-06-03
发明人: ABKEN, Hinrich , HOMBACH, Andreas , EHLING, Manuel
IPC分类号: C07K16/28 , A61K35/17 , C07K14/725 , C07K14/705 , C12N5/0783 , A61P37/00 , C07K14/715 , A61K39/00
摘要: The present invention relates to proteins which comprise (i) a CD25-specific binding domain, (ii) a linker domain, connecting domain (i) and domain (iii), (iii) a transmembrane domain, and (iv) a signalling domain. The present invention furthermore relates to nucleic acids encoding the proteins, expression constructs for expressing the protein in a host cell and host cells. The present invention further relates to pharmaceutical compositions comprising said protein(s), nucleic acid(s), expression construct(s) or host cell(s). The proteins of the invention are CD25-specific chimeric antigen receptors that are suitable for generating CD25- specific immune cells, which can be used e.g. in the treatment of inflammation.
-
公开(公告)号:WO2019025561A1
公开(公告)日:2019-02-07
申请号:PCT/EP2018/071035
申请日:2018-08-02
发明人: BROCK, Damian , KUNZ, Werner , TOURAUD, Didier
IPC分类号: C10L1/02
摘要: The present invention relates to fuel derived from renewable resources. More specifically, the present invention provides a composition which can be used as a fuel and a mixture which can be added to one or more C 8-22 fatty acid triglycerides in order to provide a fuel. The composition of the present invention comprises one or more C 8-22 fatty acid triglycerides, one or more C 8-22 fatty acid C 1-6 alkyl esters, a furan derivative which is a compound comprising at least one furan moiety or tetrahydrofuran moiety and which comprises from 5 to 15 carbon atoms and from 1 to 10 heteroatoms selected from N, O and S, and a glycerol derivative other than C 8-22 fatty acid triglycerides and/or a terpene derivative. The mixture according to the present invention differs from the composition essentially in that it contains at most very low amounts of C 8-22 fatty acid triglycerides. This mixture may be combined with locally produced oils to constitute the composition which can then be used as a fuel.
-
公开(公告)号:WO2018189390A1
公开(公告)日:2018-10-18
申请号:PCT/EP2018/059585
申请日:2018-04-13
IPC分类号: G01N33/576
摘要: The present invention relates to measurement of immunological parameters as a means to predict time-to-viral clearance in patients with chronic Hepatitis C Virus (HCV) infection under direct acting antiviral (DAA) therapy. The present invention provides a principle and methods for stratifying individuals into suitable treatment groups and personalized methods of treatment for such individuals.
-
公开(公告)号:WO2016020369A1
公开(公告)日:2016-02-11
申请号:PCT/EP2015/067920
申请日:2015-08-04
发明人: MAHBOOBI, Siavosh , SELLMER, Andreas , PONGRATZ, Herwig , LEONHARDT, Michel , KRÄMER, Oliver , BÖHMER, Frank-Dietmar , KELTER, Gerhard
IPC分类号: C07D471/12 , C07D471/18 , C07C259/00 , A61P35/00 , A61K31/166 , A61K31/4375 , A61K31/439
CPC分类号: C07D471/18 , C07C259/06 , C07C259/10 , C07C2603/18 , C07D455/03 , C07D471/12 , C07D471/14 , C07D471/22
摘要: The present invention relates to small molecule compounds and their use as HDAC inhibitors and in the treatment of various diseases, such as cancer. The present invention further relates to methods of synthesizing the compounds and methods of treatment. H − L(HA), H is a head group selected from (head group 1), (head group 2), (head group 3), (head group 4), (head group 5) and (head group 6).
摘要翻译: 本发明涉及小分子化合物及其作为HDAC抑制剂的用途以及各种疾病如癌症的治疗。 本发明还涉及合成化合物的方法和治疗方法。 H-L(HA),H是选自(头组1),(头组2),(头组3),(头组4),(头组5)和头组6的头组。
-
公开(公告)号:WO2015189374A1
公开(公告)日:2015-12-17
申请号:PCT/EP2015/063138
申请日:2015-06-12
IPC分类号: C07C67/36 , C07C201/16
CPC分类号: C07C201/14 , C07C67/36 , C07C69/76 , C07C69/78 , C07C69/92 , C07C205/57
摘要: Es wird ein Verfahren zur Herstellung von Aryl- und Heteroarylcarbonsäureestern Ar- COOR' beschrieben, wobei ein Aryl- oder Heteroaryldiazoniumsalz Ar-N2+-X- mindestens teilweise gelöst in einem Alkohol R'-OH unter einem Druck von 10 bis 100 bar mit CO in Gegenwart eines Fotokatalysators und von Licht umgesetzt wird, wobei Ar eine substituierte oder unsubstituierte Aryl- oder Heteroarylgruppe ist, wobei die Aryl- oder Heteroarylgruppe mit einem oder mehreren Substituenten ausgewählt aus Halogenen, stickstoffhaltigen Gruppen, wie Nitro-, Amino-, Amido- oder Cyanogruppen, organischen Gruppen wie linearen, verzweigten oder cyclischen gesättigten und ungesättigten Alkyl- oder Alkoxygruppen mit bis zu 20 Kohlenstoffatomen, linearen oder cyclischen Estergruppen, Aryl, Aryloxy, Heteroarylgruppen, substituierten Amino- und Amidogruppen, wobei die Substituenten Alkyl-, Alkenyl-, Alkinyl-, Aryl- oder Heteroarylgruppen, sein können, wobei X- ein Anion ist, wobei R' ein linearer, verzweigter oder cyclischer Alkyl-, Alkenyl- oder Alkinylrest mit bis zu 30 C-Atomen ist, der unsubstituiert oder wie oben substitutiert sein kann.
摘要翻译: 中描述了一种方法用于制备芳基和HeteroarylcarbonsäureesternAR- COOR的”,其中Ar是芳基或Heteroaryldiazoniumsalz N2 + X-至少部分地溶解在醇R'-OH的10的压力下,以100巴的CO在 光催化剂的存在下并通过光来实现,其特征在于,Ar是取代或未取代的芳基或杂芳基,其特征在于,选自卤素具有一个或多个取代基的芳基或杂芳基,含氮基团,如硝基,氨基,酰氨基或氰基 有机基团,例如直链,支链或环状的饱和和不饱和的烷基或具有至多20个碳原子,直链或环状酯基,芳基,芳氧基,杂芳基,取代的氨基和酰氨基烷氧基,其中取代基是烷基,烯基,炔基 基,芳基或杂芳基,可以是,其特征在于,X-是阴离子,其中R“是直链,支链 或环状的烷基,烯基或炔基基团具有至多30个碳原子,其可以是未取代的或如上取代。
-
公开(公告)号:WO2013068397A1
公开(公告)日:2013-05-16
申请号:PCT/EP2012/072027
申请日:2012-11-07
CPC分类号: A61K47/48215 , A61K9/0024 , A61K9/0051 , A61K31/765 , A61K31/787 , A61K47/34 , A61L27/18 , A61L27/38 , A61L27/52 , A61L27/54 , A61L2430/16 , C08J3/075 , C08L71/02
摘要: Gegenstand der vorliegenden Erfindung sind Hydrogele sowie deren Herstellung durch Quervernetzung von Makromonomeren mittels Diels-Alder Reaktion. Die beschriebenen Hydrogele, die in-situ gelieren können, eignen sich unter anderem als Biomaterial für medizinische Anwendungen, als Gerüstmaterial für lebende Zellen und als Trägersystem für die kontrollierte Freigabe von Arzneistoffen.
摘要翻译: 本发明的目的是水凝胶和通过第尔斯 - 阿尔德反应的交联的大分子单体及其制备。 可以在原位凝胶中描述的水凝胶,适合等等作为用于医疗应用的生物材料,作为用于活细胞的支架材料和作为用于药物的受控释放的载体系统。
-
公开(公告)号:WO2009024296A1
公开(公告)日:2009-02-26
申请号:PCT/EP2008/006725
申请日:2008-08-14
IPC分类号: G01N33/50
CPC分类号: G01N33/6887 , G01N33/6893 , G01N2800/10 , G01N2800/102 , G01N2800/105
摘要: The present invention is related to the use of AP-2 epsilon as a marker for a disease.
摘要翻译: 本发明涉及使用AP-2ε作为疾病的标志物。
-
-
-
-
-
-
-
-
-